This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Polonis, V. R.
Right arrow Articles by Birx, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Polonis, V. R.
Right arrow Articles by Birx, D. L.

 Previous Article  |  Next Article 

Journal of Virology, August 2003, p. 8570-8576, Vol. 77, No. 15
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.15.8570-8576.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Resistance Is Associated with the Syncytium-Inducing Phenotype and Lower CD4 Cell Counts in Subtype CRF01_AE-Infected Patients

Victoria R. Polonis,1,2* Mark S. de Souza,1,2 Janice M. Darden,2,3 Somsak Chantakulkij,1 Thippawan Chuenchitra,1 Sorachai Nitayaphan,1 Arthur E. Brown,1 Merlin L. Robb,2 and Deborah L. Birx4

Armed Forces Research Institute of Medical Sciences, Bangkok 10400,1 Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand,3 The Henry M. Jackson Foundation,2 Walter Reed Army Institute of Research, Rockville, Maryland 208504

Received 13 January 2003/ Accepted 8 May 2003

A number of human immunodeficiency virus type 1 (HIV-1) non-B-subtype products have been developed for present or future vaccine trials; in Thailand, several studies using subtype B and/or CRF01_AE vaccines have been conducted. To better characterize the biologic properties of these subtypes, 70 HIV-1 subtype B and E isolates were phenotyped as syncytium-inducing (SI) or non-syncytium-inducing (NSI) isolates and assessed for sensitivity to neutralizing antibody (NAb). A significantly higher number of NSI subtype E viruses were neutralization sensitive than SI subtype E viruses (P = 0.009), while no association between viral phenotype and sensitivity to NAb was observed for subtype B (P = 0.856), suggesting a difference in the neutralization patterns of subtypes B and E. Strikingly, concurrent CD4 T-cell numbers were significantly lower for subtype E-infected patients whose isolates were more resistant to NAb, both for the overall study group (P < 0.001) as well as for the 22 patients with NSI isolates (P = 0.013). Characterization of the evolution of biologic properties of both B and non-B HIV-1 subtypes will provide a clearer understanding of the repertoire of antibodies that must be elicited for a vaccine to be effective against all phenotypes and subtypes.


* Corresponding author. Mailing address: The Henry M. Jackson Foundation, Suite 200, 13 Taft Ct., Rockville, MD 20850. Phone: (301) 762-8308. Fax: (301) 762-4177. E-mail: vpolonis{at}hivresearch.org.


Journal of Virology, August 2003, p. 8570-8576, Vol. 77, No. 15
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.15.8570-8576.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Nardacci, R., Antinori, A., Larocca, L. M., Arena, V., Amendola, A., Perfettini, J.-L., Kroemer, G., Piacentini, M. (2005). Characterization of Cell Death Pathways in Human Immunodeficiency Virus-Associated Encephalitis. Am. J. Pathol. 167: 695-704 [Abstract] [Full Text]  
  • Brown, B. K., Darden, J. M., Tovanabutra, S., Oblander, T., Frost, J., Sanders-Buell, E., de Souza, M. S., Birx, D. L., McCutchan, F. E., Polonis, V. R. (2005). Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines. J. Virol. 79: 6089-6101 [Abstract] [Full Text]